Previous Page  4 / 48 Next Page
Information
Show Menu
Previous Page 4 / 48 Next Page
Page Background

Outline

ü

ALK fusions as oncogenic driver

ü

Diagnostic tools

ü

Clinical characteristics NSCLC ALK+

ü

Development and achievements with ALK TKIs

ü

Sequencing treatments in ALK+

ü

Resistance mechanisms